Thrombosis
Conference Coverage
VIDEO: Rivaroxaban gives safer protection to atrial fib patients post PCI
NEW ORLEANS – The puzzle of how to safely prevent thrombotic events in patients with atrial fibrillation who receive a coronary stent now has a...
Conference Coverage
Scoring formula consolidates stroke, bleeding risk in atrial fib patients
ROME
Conference Coverage
VIDEO: Two PCI vs. CABG trials produce conflicting results
Two large, randomized comparisons of coronary stenting and bypass surgery for patients with less complex left main CAD had sharply different...
Conference Coverage
VIDEO: Bioresorbable Absorb unexpectedly humbled by metallic DES
WASHINGTON – The bioabsorbable vascular scaffold bubble suddenly burst with the first 3-year follow-up data from a randomized trial that...
Conference Coverage
Pulmonary embolism common in patients hospitalized for syncope
Pulmonary embolism was identified in approximately 17% of adults hospitalized for a first episode of syncope, according to a recent study.
Article
FDA reaffirms rivaroxaban’s atrial fib efficacy in ROCKET AF
The Food and Drug Administration reaffirmed its confidence in the data supporting the claim that rivaroxaban (Xarelto) is a safe and effective...
Conference Coverage
Algorithm for suspected pulmonary embolism safely cut CT rate
ROME – A simplified algorithm for management of patients with suspected pulmonary embolism safely excluded the disorder with less need for CT...
Conference Coverage
Aspirin not prescribed appropriately to cut cardiovascular risk in diabetes
MUNICH – Many diabetes patients who should be taking aspirin for cardiovascular risk reduction are not doing so, and many who should not be taking...
From the Journals
Has mystery of exercise-intolerant chronic thromboembolic disease been solved?
Key clinical point: This study identifies key clinical features of the pathophysiology of exercise intolerance in chronic thromboembolic disease (...
Conference Coverage
Optimal medical therapy doesn’t affect DAPT efficacy
ROME – The decision to use DAPT beyond 12 months should be made irrespective of OMT use.
Conference Coverage
Decision rule identifies unprovoked VTE patients who can halt anticoagulation
ROME – Half of women who have a first unprovoked venous thromboembolism can safely be spared lifelong anticoagulation through application of the...